Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711936 | 0.92 | APP (0.48) | ALDH1A1CYP1A1CYP1B1GRM5ABL1 | |
| SCHEMBL674040 | 0.81 | ALDH1A1 (0.65) | ALDH1A1CYP1A1CYP1B1GRM5ABL1 | |
| SCHEMBL31277232 | 0.80 | ALDH1A1 (0.41) | ALDH1A1CYP1A1CYP1B1GRM5ABL1 | |
| SCHEMBL852844 | 0.80 | GRM5 (0.59) | GRM5 | |
| SCHEMBL1476713 | 0.80 | GRM5 (0.58) | CYP1A1CYP1B1GRM5CYP1A2CYP3A4 | |
| SCHEMBL673162 | 0.78 | APP (0.55) | ALDH1A1GRM5APPL3MBTL1TDP1 | |
| SCHEMBL1478000 | 0.78 | LOX (0.35) | — | |
| SCHEMBL19993574 | 0.78 | HSD17B1 (0.46) | ALDH1A1GAA | |
| SCHEMBL29849432 | 0.78 | HSD17B1 (0.46) | ALDH1A1GAA | |
| SCHEMBL25333167 | 0.77 | ALDH1A1 (0.38) | ALDH1A1GRM5L3MBTL1TDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814462-B2 | Functionalized cyclic polymers and methods of preparing same | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-11-14 | — | — | US | claimed |
| US-20220056167-A1 | Functionalized Cyclic Polymers and Methods of Preparing Same | NATIONAL SCIENCE FOUNDATION | 2022-02-24 | — | — | US | claimed |
| WO-2020223672-A1 | FUNCTIONALIZED CYCLIC POLYMERS AND METHODS OF PREPARING SAME | UNIVERSITY OF FLORIDA RESEARCHFOUNDATION, INC. (US) | 2020-11-05 | — | — | WO | claimed |
| US-11814462-B2 | Functionalized cyclic polymers and methods of preparing same | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11572353-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-11572353-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| EP-3517535-B1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| CN-109843873-B | Alkyne heterocyclic compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220056167-A1 | Functionalized Cyclic Polymers and Methods of Preparing Same | NATIONAL SCIENCE FOUNDATION | 2022-02-24 | — | — | US | disclosed |
| US-20210332027-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-20210332027-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| WO-2009126700-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS AS COSMETICS OR THERAPEUTICS FOR SKIN CONDITIONS | KENT STATE UNIVERSITY (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2008157745-A1 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157787-A2 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7094809-B2 | Topical administration of dihydroxytoluene to block viral replication | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2006-08-22 | — | — | US | disclosed |
| US-20030203974-A1 | Methods for treating subjects infected with herpes virus or Neisseria gonorrheae | DOCHERTY JOHN (US) | 2003-10-30 | — | — | US | disclosed |
| US-6599945-B2 | Administering a hydroxylated tolan to the host cell of a patient having or suspected having an infection induced by herpes virus | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE | 2003-07-29 | — | — | US | disclosed |
| EP-1311254-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR i NEISSERIA GONORRHEAE /i | Northeastern Ohio Universities (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020103262-A1 | Methods for treating subjects infected with a herpes virus or neisseria gonorrheae | KENT STATE UNIVERSITY | 2002-08-01 | — | — | US | disclosed |
| WO-2002013764-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR NEISSERIA GONORRHEAE | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572353-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | FGFR1, FGFR4, FGFR3 | ALDH1A1 329/4885CYP1A1 673/4885CYP1B1 112/4885 |
| US-20210332027-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FGFR1, FGFR4, FGFR3 | ALDH1A1 329/4885CYP1A1 673/4885CYP1B1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.